Comparative Study of Efficacy and Adverse Effects of Metformin Plus Empagliflozin Versus Metformin Plus Sitagliptin in Diabetes Mellitus Type II Patients
Abstract
Introduction: This study aims to compare the efficacy and adverse effects of metformin combined with empagliflozin versus metformin combined with sitagliptin in Type II DM patients in Pakistan. Given the rising prevalence of diabetes in Pakistan, evaluating these widely used combination therapies in a local population is essential for optimizing treatment strategies. This research will provide valuable insights into glycemic control and safety profiles in a population with unique genetic, dietary, and lifestyle factors, which are often underrepresented in global studies. Materials and Procedures: This single-blinded RCT enrolled 112 patients aged 35–65 with HbA1c 7–9%, diabetes >1 year. Patients were randomized into two groups: Group A received Metformin plus Empagliflozin, and Group B received Metformin plus Sitagliptin. Exclusions included irregular medication, prior hypoglycemic use, high creatinine, or glucose-altering drugs. HbA1c was measured monthly; compliance and side effects were monitored. Results: In my research, patients treated with metformin + empagliflozin had a higher likelihood of being in the metformin + empagliflozin group than those treated with metformin + sitagliptin (48.21% vs. 26.79%, respectively) if their HbA1c was under 7%. Side effects with empagliflozin are less than sitagliptin i.e. diarrhea (3.57% vs 8.93%), rash (0.0% vs 5.36%), hypoglycemia (12.50% vs 16.07%), UTI (0.0% vs 7.14%) and increased urination (19.64% vs 10.71%) respectively.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 112 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.